

Applicant : Katsunari Te [REDACTED] al.  
Serial No. :  
Filed : Herewith  
Page : 3

Attorney's Docket No.: 06501-077001

REMARKS

Claim 1-32 are pending, claims 3-6, 8, 13, 14, 16, 21, 23, 27, 29 and 31 having been amended to delete multiple dependency. No new matter has been added.

Attached is a marked-up version of the changes being made by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 26 Apr 1 2001

Janis K. Fraser 47,443  
Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

20253588.doc

20253588.doc

**Version with markings to show changes made**

**In the claims:**

Claims 3-6, 8, 13, 14, 16, 21, 23, 27, 29 and 31 have been amended as follows:

3. (Amended) The pharmaceutical composition of claim 1 [or 2], wherein the cytokine is interferon  $\gamma$  which is a cytokine produced by Th1 type T cells, or interleukin 4 which is a cytokine produced by Th2 type T cells.

4. (Amended) The pharmaceutical composition of [any one of claims 1 to 3] claim 1, wherein the arthrosis is rheumatoid arthritis.

5. (Amended) The pharmaceutical composition of [any one of claims 1 to 3] claim 1, wherein the arthrosis is osteoarthritis.

6. (Amended) The pharmaceutical composition of [any one of claims 1 to 5] claim 1, wherein the substance is a protein substance.

8. (Amended) The pharmaceutical composition of [any one of claims 1 to 5] claim 1, wherein the substance is a non-protein substance.

13. (Amended) The pharmaceutical composition of [any one of claims 10 to 12] claim 10, wherein the inflammation is hepatitis.

14. (Amended) The pharmaceutical composition of [any one of claims 10 to 13] claim 10, wherein the substance is a protein substance.

16. (Amended) The pharmaceutical composition of [any one of claims 10 to 13] claim 10, wherein the substance is a non-protein substance.

21. (Amended) The pharmaceutical composition of [any one of claims 18 to 20] claim 18, wherein the substance is a protein substance.

23. (Amended) The pharmaceutical composition of [any one of claims 18 to 20] claim 18, wherein the substance is a non-protein substance.

27. (Amended) The pharmaceutical composition of claim 25 [or 26], wherein the substance has an activity in inhibiting proliferation of AILIM-expressing cells or in inhibiting production of a cytokine by AILIM-expressing cells.

29. (Amended) The pharmaceutical composition of [any one of claims 25 to 28] claim 25, wherein the substance is a protein substance.

31. The pharmaceutical composition of [any one of claims 25 to 28] claim 25, wherein the substance is a non-protein substance.